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Objective: The initial palliative procedure for patients born with hypoplastic left heart
syndrome and related single right ventricle anomalies, the Norwood procedure, remains among the highest risk procedures in congenital heart surgery. The classic Norwood procedure provides pulmonary blood flow with a modified Blalock–Taussig
shunt. Improved outcomes have been reported in a few small, nonrandomized studies
of a modification of the Norwood procedure that uses a right ventricle–pulmonary
artery shunt to provide pulmonary blood flow. Other nonrandomized studies have
shown no differences between the two techniques.
Methods: The Pediatric Heart Network designed a randomized clinical trial to compare outcomes for subjects undergoing a Norwood procedure with either the right ventricle–pulmonary artery or modified Blalock–Taussig shunt. Infants with a diagnosis
of single, morphologically right ventricle anomaly who are undergoing a Norwood
procedure are eligible for inclusion in this study. The primary outcome is death or cardiac transplant 12 months after random assignment. Secondary outcomes include
postoperative morbidity after Norwood and stage II palliation procedures, right ventricular function and pulmonary arterial growth at stage II palliation, and neurodevelopmental outcomes at 14 months old. Incidence of adverse events will also be
compared between treatment groups.
Conclusion: This study will make an important contribution to the care of patients with
hypoplastic left heart syndrome and related forms of single, morphologically right
ventricle. It also establishes a model with which other operative interventions for
patients with congenital cardiovascular malformations can be evaluated in the future.

R

efinements in technique, perfusion management, and postoperative care have
improved outcomes for patients born with hypoplastic left heart syndrome
(HLHS) and other single, morphologically right ventricle (RV) conditions
who undergo the Norwood procedure. Nonetheless, patients with these lesions continue to have a high mortality.1 In the classic Norwood (stage I palliation) procedure,
pulmonary blood flow is provided by a modified Blalock–Taussig shunt (MBTS). A
modification of this procedure involves placing a shunt from the (RV to the PA, rather
than the standard MBTS, to provide pulmonary blood flow.2
Theoretic advantages of the RV-PA shunt are predominantly associated with absence of diastolic blood flow from the systemic circulation into the pulmonary circulation. They include (1) a more stable postoperative course, (2) increased coronary
arterial flow because of the lack of aortic diastolic runoff, (3) improved weight gain
related to improved splanchnic perfusion, and (4) lower interstage mortality.3-7 Potential disadvantages of the RV-PA shunt include the following: (1) the ventriculotomy,
which could predispose toward ventricular dysfunction, arrhythmias, and false
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Newborn with Single RV Anomaly

Screening for Eligibility

Randomization

Norwood with MBTS

aneurysms; (2) free pulmonary insufficiency, resulting in
ventricular dilation, (3) decreased PA growth related to the
lack of forward flow during diastole, and (4) need for earlier
stage II procedure because of hypoxemia.1,5,8-10
No prospective randomized trial has compared patient
outcomes after a Norwood procedure with the MBTS with
those after one incorporating the RV-PA shunt. Several
case series that used historical series of patients with
MBTS as a control group reported improved short-term survival with the RV-PA shunt.2,4,11,12 In contrast, a retrospective review comparing contemporaneous results of stage 1
reconstruction with the MBTS versus the RV-PA shunt performed during the same time period showed no differences in
mortality or short-term outcomes.13 A second study also
showed no difference in early morbidity and mortality between the two shunts, although the patients who underwent
the RV-PA shunt were discharged from the hospital earlier
than were those who underwent the MBTS.9 That same cohort was later reported to have no difference in mortality or
morbidity after stage II palliation between MBTS and RVPA shunt groups.5 All these studies are confounded by the
fact that the type of shunt placed was determined by surgeon
preference. In addition, the anatomic subtypes differed significantly between cohorts. Thus there is a need for a rigorous,
randomized clinical trial to determine the optimal strategy.
The purpose of this report is to describe the design and rationale of a multisite, randomized clinical trial to compare outcomes associated with the RV-PA shunt with those of the
MBTS in a prospective and randomized fashion.

Materials and Methods

Norwood with RV-PA Shunt

Monitor Post-operative and Inter-stage
Course; Echocardiogram, Genetics

Pre-Stage II Procedure
Anthropometry, Echocardiogram and Catheterization (optional)

Stage II Procedure

Evaluation of 12-month Mortality or Transplantation

14-month Anthropometric, Neurodevelopmental,
Echocardiographic, and Genetics Evaluations (optional),
End of Study

Figure 1. Flow diagram for trial. RV, Right ventricle; MBTS, modified Blalock–Taussig shunt; PA, pulmonary artery.

the study design is shown in Figure 1. An independent Data and
Safety Monitoring Board and an independent medical monitor
have been established by the National Heart, Lung, and Blood Institute to monitor this trial for data quality and safety.

Subject Selection
Subject selection criteria were defined to ensure a relatively homogeneous group of subjects with a functionally single ventricle lesion
characterized by a single morphologically RV. Inclusion and exclusion criteria are shown in Table 1.

Study Overview
This trial will test the hypothesis that the RV-PA shunt is associated
with a decrease relative to the MBTS in the frequency of the combined end point of mortality or transplant at 12 months after random
assignment. We plan to enroll 466 infants to be randomly assigned
to undergo either MBTS or RV-PA shunt. The concept for this study
was developed by investigators at the University of Michigan Medical School, the Children’s Hospital of Philadelphia, Children’s
Hospital of Wisconsin, and Children’s Hospital Boston, who collaborated with the National Heart, Lung, and Blood Institute–funded
Pediatric Heart Network (PHN)14 to develop the final study design.
The study is being conducted at 14 clinical centers. A flow chart of

Randomization and Stratification
Subjects are assigned to treatment group with randomly permuted
blocks within strata defined by the presence or absence of aortic atresia and the presence or absence of obstructed pulmonary venous return.15-18 Obstructed pulmonary venous return is defined by the use
of postnatal intervention, including balloon septostomy, open atrial
septectomy, or urgent Norwood procedure. Aortic atresia is defined
by 2-dimensional and color Doppler echocardiographic findings interpreted at the local center. Because of potential differences in surgeon experience and operative techniques, dynamic balancing by
surgeon ensures that treatment arm totals are balanced within each
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Abbreviations and Acronyms
APOE 5 apolipoprotein E genotype
CPB 5 cardiopulmonary bypass
HLHS 5 hypoplastic left heart syndrome
MBTS 5 modified Blalock–Taussig shunt
PA
5 pulmonary artery
PHN 5 Pediatric Heart Network
RV
5 right ventricle
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TABLE 1. Inclusion and exclusion criteria
Inclusion criteria
 Diagnosis of hypoplastic left heart syndrome or related single, morphologically right ventricle anomaly
 Planned Norwood procedure
 Informed consent of parent or legal guardian
Exclusion criteria
 Single, morphologically left ventricle anomaly
 Preoperative identification of anatomic features rendering either modified Blalock–Taussig shunt or right ventricle–pulmonary artery
shunt technically impossible
 Any major congenital abnormality (eg, congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extracardiac disorder
(eg, meconium aspiration with need for high-frequency ventilation, persistent renal failure requiring dialysis) that investigator
considered could independently affect likelihood of subject meeting primary end point

surgeon’s case load and will avoid excessively small stratum sizes
that might result from use of more than two stratification factors.

Technical Considerations of Surgery

CHD

Each center will strive to maintain a consistent approach to perioperative care and the conduct of the operation, regardless of the shunt
group to which the subject is randomly assigned, for the duration
of the trial. These variables include such techniques as cardiopulmonary bypass (CPB, including the use of regional cerebral perfusion,
hematocrit levels, and methods of pH monitoring) and management
in the intensive care unit before and after surgery. Despite these efforts to standardize the care for the duration of the trial, however,
management techniques invariably change with time. To minimize
the impact of these changes, permuted block randomization will be
used, as mentioned previously. In addition, extensive data on perioperative management will be recorded to allow analysis of significant changes in management during the trial time frame.
The MBTS and RV-PA shunts are constructed of unvalved polytetrafluoroethylene tube grafts with standard surgical techniques.2,16
Features of cardiac anatomy recognized in the operating room after
random assignment occasionally render the performance of the
MBTS or RV-PA shunt technically infeasible. Although every effort
is made to use the shunt to which the subject has been randomly assigned, the surgeon may choose an alternative shunt at any time during the operation if it is deemed to be in the subject’s best interest
because of unanticipated anatomic constraints. If the innominate artery is not appropriate for the MBTS, such as in the scenario of an
aberrant right subclavian artery and inadequate caliber right carotid
artery, the subject will be considered for an aortopulmonary shunt.
Because a shunt arising from the aorta is a shunt from a systemic artery to the PA, its use will not be considered a treatment crossover.
On rare occasions, if the surgeon considers that the MBTS or another shunt from a systemic artery to the PA cannot be performed,
a crossover will occur. Another possibility is the finding of a large
conal branch on the RV free wall in the area of the proposed origin
of the RV-PA shunt. In this case, the subject will also cross over to
the alternative shunt. It is also possible that after the placement of the
initial randomly assigned shunt, the subject may not be able to be
separated successfully from CPB. The surgeon may place another
type of shunt in an attempt to save the subject’s life.

Study Measurements and Subject Follow-up
Baseline data. Demographic and preoperative data include
pregnancy history, fetal diagnosis, birth weight, race, gender, gesta-

tional age, Apgar scores, clinical status and anatomic diagnosis at
presentation, occurrence of important preoperative complications,
age at operation, and genetic evaluation findings (if performed).
All centers perform 2-dimensional echocardiographic studies,
which are reviewed both locally and in the 2-dimensional echocardiography core laboratory to evaluate anatomy and ventricular function. Centers with 3-dimensional echocardiography capability also
collect these studies for local interpretation and review by the 3dimensional echocardiography core laboratory. Any additional interventions and important events, as defined by the protocol, are
recorded.
Follow-up visits. The schedule of data collection is summarized
in Table 2. Follow-up data are obtained at five times: (1) during hospitalization for the Norwood procedure, (2) before the stage II palliation, (3) during hospitalization for the stage II palliation, (4) 12
months after random assignment, and (5) at age 14 months. Specific
data and studies include the following:
 echocardiographic and Doppler images obtained for analysis
after the Norwood procedure, before the stage II palliation
and at age 14 months;
 height, weight, and head circumference measured at the time
of each echocardiogram;
 apolipoprotein E genotype (APOE) obtained by buccal swab
from subjects with consent during the hospitalization for the
Norwood procedure (consent for genotyping not required for
participation in the main trial);
 Cardiac catheterization data and images, if a routine cardiac
catheterization is performed for clinical indications before
the stage II palliation;
 Vital status and whether a heart transplant has been performed (collected 12 months after random assignment only).
 The Bayley Scales of Infant Development–II (Harcourt Assessment, Inc, San Antonio, Tex), MacArthur-Bates Communicative Development Inventories (Singular Publishing
Group, San Diego, Calif), Hollingshead Four Factor Scale
(Four-factor index of social status [unpublished manuscript];
Yale University, New Haven, Conn), and Functional Status
II–Revised questionnaire (Albert Einstein College of Medicine, Bronx, NY) at 14 months old.
Echocardiographic data, APOE genotype, and cardiac catheterization data are centrally interpreted in PHN core laboratories. To
cover long-term follow-up of this unique patient population, the
consent form includes permission to contact each family annually
until the subject reaches the age of 5 years.
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TABLE 2. Schedule of trial measurements
Baseline
Measurement

Study entry

Medical history
Height, weight, and head circumference
Anatomic subtype
Intensive care unit and hospital courses
Echocardiogram
Catheterization*
Apolipoprotein E genotypey
Death or transplant
Neurodevelopmental evaluation
Clinical genetics evaluationy

X
X
X

Follow-up
Norwood hosp

Discharge

Before stage II

X
X

X
X

X

X
X

X
X

Stage II hosp

Age 12 mo

Age 14 mo

X
X
X
X

X
X
X

X
X

Trial Outcomes
The primary outcome is death or cardiac transplant by 12 months after randomization. Secondary outcomes are listed in Table 3.

Blinding of Treatment Group Assignment
This trial is not blinded with respect to knowledge of treatment assignment. Blinding is not feasible for most of the personnel caring
for the subjects, because the treatment strategies produce differences
in physical examination findings and in the follow-up studies performed for the secondary end points, such as echocardiography
and cardiac catheterization. Only the specialists who perform the
neurodevelopmental testing and the APOE genotyping are blinded
to treatment assignment.

Statistical Considerations
For the primary trial result, the proportion of subjects with MBTS
versus RV-PA shunt reaching the primary trial end point by 12
months after randomization will be compared with a Fisher exact
test. Furthermore, to test the hypothesis that differences in the surgical strategies are present early, a comparison of the primary end
point in the two trial arms will be conducted with the Kaplan–Meier
method for estimation and the Gehan–Wilcoxon test, which places
more weight on early failure times because of weights determined
by risk set sample size. A competing risks analysis (death vs transplant vs stage II surgery performed vs no progression through additional stages) will also be conducted to characterize subject risk
more fully by treatment group.
All primary analyses will be performed on an intention-to-treat
basis. This approach implies that the rare randomly allocated subject
who receives neither trial shunt (eg, in the event of death between
assignment and the Norwood procedure) would remain classified
in the assigned surgical group for analysis. If it is clear that the decision not to proceed with the Norwood procedure has not been
influenced by knowledge of the assigned shunt, however, then no
bias is incurred, intention-to-treat is preserved, and those subjects
will be excluded from analysis. A review panel will evaluate each
case in which a randomly allocated subject receives neither trial
shunt. If the review panel determines that the decision to use neither
trial shunt was clearly not influenced by treatment assignment (eg,
subject dies before surgery), then that subject will be excluded

from all analyses. Primary outcome data will be collected for these
subjects so that the impact of the exclusions on primary analysis
results can be assessed.
Secondary analyses will compare treatment groups as follows:
(1) with covariate-adjusted analysis, (2) according to which shunt
was actually in place at the conclusion of the operative procedure,
and (3) after exclusion of any randomly assigned subjects subsequently found to have been ineligible for the trial at the time of enrollment.
Treatment assignment by prespecified subgroup interaction
analyses are planned to estimate the effects of birth weight, preoperative tricuspid regurgitation, type of cerebral perfusion during
stage I palliation, experience of the surgeon, and center volume
(Table 4).
To monitor the trial for large treatment differences, three formal
interim analyses are planned, timed to occur when one quarter, one
half, and three quarters of subjects would be expected to reach the
12-month visit. An O’Brien–Fleming stopping boundary with
a Lan–DeMets adjustment will be used for this purpose. Adverse
event rates by trial arm, as well as death and transplantation rates
in aggregate, are reported to the Data and Safety Monitoring Board
twice a year. To preserve the type I error rate for primary analysis,
death and transplantation rates by treatment arm are reported during
prespecified interim analyses only.
This trial is powered to detect differences in the primary composite end point (death or cardiac transplant) by 12 months after random
assignment. A review of previous data from the participating centers
for infants born in 2002 and 2003 was performed to calculate an estimate of the incidence of death or cardiac transplant for each shunt
under consideration. For subjects undergoing a Norwood procedure
with MBTS at least 1 year earlier, the incidence of death or transplant by 12 months after surgery was 28% (65/236). The expected
mortality for the RV-PA shunt was based on the three member centers routinely performing the RV-PA shunt exclusively or in a significant proportion of their Norwood procedures. The data on Norwood
procedures with RV-PA shunts were sparse, and not all patients had
reached 1 year old. Because previously reported data indicate that
events after the stage II procedure are rare,11,19 all deaths and cardiac
transplants, regardless of whether the patient had reached 1 year of
age, were counted. For subjects receiving a RV-PA shunt at the three
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hosp, Hospitalization. *Not mandated by protocol, performed at discretion of attending cardiologist. yNot mandated by protocol, performed only with consent
of family.
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Morbidity after the Norwood procedure
1. Open sternum (yes or no)
2. Extracorporeal membrane oxygenation (yes or no)
3. Cardiopulmonary resuscitation (yes or no)
4. Time to initial extubation (h)
5. Duration of ventilation (total d)
6. Length of intensive care unit stay (d)
7. Length of hospital stay from day of surgery (d)
Incidence of unintended cardiovascular interventional procedures (composite and individual)
1. Balloon dilation of shunt or branch pulmonary arteries
2. Stent placement in shunt or branch pulmonary arteries
3. Shunt revision
4. Crossover between MBTS and RV-PA shunt
5. Balloon dilation, stent placement, or surgical revision of neoaorta
6. PA reconstructions other than those undertaken as standard component of stage II procedure
Evaluation of RV function by 2-dimensional echocardiography
1. Right ventricular BSA-adjusted Z scores for diastolic and systolic volumes and age-adjusted Z scores for ejection fraction
2. Absolute values for diastolic and systolic volumes and ejection fraction
3. dP/dt obtained from the tricuspid regurgitation jet
4. Severity of tricuspid regurgitation
5. Doppler tissue imaging of RV
a. Systolic annular acceleration and peak velocity
b. Isovolumic myocardial acceleration
Pulmonary arterial growth
1. Angiographic PA cross-sectional area, as determined by the Nakata index
2. Ratio of distal to proximal PA diameter, measured by angiography
3. Incidence of angiographically discrete PA stenosis
4. Change in echocardiographic Nakata index from Norwood procedure to stage II procedure
Stage II perioperative morbidity
1. Cardiopulmonary resuscitation (yes or no)
2. Time to initial extubation (hours)
3. Duration of ventilation (total d)
4. Length of intensive care unit stay (d)
5. Length of hospital stay from day of stage II surgery (d)
Neurodevelopmental outcome
1. Bayley Scales of Infant Development II
2. MacArthur Communicative Developmental Index
3. Functional Status II–Revised questionnaire
MBTS, Modified Blalock–Taussig shunt; RV, right ventricle; PA, pulmonary artery, BSA, body surface area, dP/dt, estimated maximum first derivative of ventricular pressure.

centers of interest, the 12-month mortality or transplant rate was assumed to be 16% (14/87). The trial was thus designed to detect
a 12% difference with 85% power at a 2-sided significance level
of .05. After 2% inflation to account for three interim analyses,
this required a total of 466 subjects.

Trial Organization
The PHN Single Ventricle Reconstruction Study Committee and
PHN Steering Committee, together with the National Heart, Lung,
and Blood Institute, are responsible for all aspects of this study.
The protocol has been approved by an independent Protocol Review
Committee and Data and Safety Monitoring Board, and by the institutional review boards at each clinical center and at the Data Coordinating Center. All centers follow the same protocol and study
procedures.

Comment
Rationale for Outcome Measures
Infants born with HLHS and related conditions have relatively
high mortality, unlike neonates with other forms of congenital
heart disease. The most fundamental research question to answer in a surgical trial in this population, therefore, is whether
the child survives to at least 1 year old, and whether the heart
requires replacement before then. The primary outcome,
death or cardiac transplant by 12 months after random assignment, reflects this clinical imperative. In addition, this definitive end point should facilitate clear interpretation of the trial
results by the medical teams taking care of these patients.
The surgical strategy could affect the postoperative course
after the stage I procedure, as well as perioperative morbidity
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TABLE 4. Subgroup factors for estimation of differential treatment effect

associated with the stage II procedure. Several standard intensive care unit measures were selected as a basis for
comparing morbidity, because decreasing intensive care
unit morbidity can improve short- and long-term outcomes
and reduce health care costs.20,21
The need for additional procedures implies incomplete
resolution of adverse hemodynamics, carries the risk of further morbidity, and may also affect long-term outcome and
health care costs. Several key procedures often used in this
population and that might plausibly differ in frequency between the trial arms were selected, including crossover
between MBTS and RV-PA shunt, shunt revision, extracorporeal membrane oxygenation, diaphragm plication, and procedures to address stenosis of the shunt, branch pulmonary
arteries, or neoaorta.
Systemic (right) ventricular function can theoretically be
compromised by either shunt. Although myocardial oxygen
delivery and RV function may be optimized when an RVPA shunt is used, RV function has not been systematically
evaluated, and the long term effects of the RV ventriculotomy
are unknown. Determining whether the type of shunt placed
at the time of the Norwood procedure affects later RV function is a crucial component of determining the best surgical
management of infants with HLHS. Establishing baseline
evaluations and standardizing echocardiographic methods
of evaluating RV function will provide early data on a
cohort of subjects who can be followed up serially through
and beyond Fontan palliation to determine whether a
difference in RV function occurs and persists long term,
and whether it eventually contributes to failure of staged
reconstruction.
The MBTS and RV-PA shunt strategies differ most significantly in their approach to providing pulmonary arterial
blood flow, which may influence subsequent PA size, rate
of growth, and stenosis. These variables are of clinical significance in their own right, but they also can affect subsequent
outcome, because small PA size is a known risk factor for patients undergoing both the stage II palliation and the Fontan
procedure.22-24 The impact of the MBTS relative to the RVPA shunt on PA growth and stenosis will be evaluated.
Multiple studies have demonstrated that preschool and
school-aged children with HLHS have neurocognitive and

behavioral abnormalities. Risk factors for such abnormalities
include underlying congenital structural central nervous system abnormalities, genetic syndromes, disturbed fetal cerebral hemodynamics, preoperative seizures, intraoperative
events related to CPB, and such postoperative factors as
low cardiac output syndrome, seizures, and longer of hospital
stay.25-29
It is hypothesized that relative to the MBTS the RV-PA
shunt may reduce neurodevelopmental impairment through
improved postoperative oxygen delivery, less steal from the
systemic circulation through the shunt into the lungs, and
higher diastolic blood pressure. Measures of neurodevelopmental status will profile the motor and cognitive capabilities
of study subjects. The effects of known modifiers of neurodevelopment will be evaluated in the analysis. One such modifier is the APOE*E2 allele, recently found to be associated
with worse neurologic outcome in patients undergoing
CPB.30 APOE genotype will be assessed as a component of
neurodevelopmental outcome.
Limitations
Blinding of subjects and caregivers is desirable in clinical trials because of the potential for bias in medical care and in adjudication of treatment outcomes. Practical considerations
preclude blinding in most surgical trials, however, including
this one. In the absence of blinding, it is important to ensure
that random assignment is conducted properly and that end
points are assessed objectively. The PHN’s standard quality
assurance process will be used for close monitoring of
screening and randomization. Although the primary end
point is a composite, most of the events are expected to be
deaths, an objective measure. If a significant number of cardiac transplants occur, the transplant criteria will be adjudicated independently in each case.
This trial, like many other studies of rare conditions, is
powered to detect a relatively large difference in the primary
end point (16% vs 28%), so a smaller but clinically important
difference might not be detected. Powering the study to detect a smaller difference, however, would require many
more subjects and thus possibly a longer study duration.
The decision to adopt the current design was made to avoid
the loss of equipoise and potential confounding changes in
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 Birth weight ,2500 g vs #2500 g
 Preoperative tricuspid regurgitation proximal jet width ,2.5 mm vs #2.5 mm determined by echocardiography
 Cerebral perfusion during stage I palliation as deep hypothermic circulatory arrest vs regional cerebral perfusion (if subject received both
types of cerebral perfusion during surgery, classification was deep hypothermic circulatory arrest)
 Experience of the surgeon as average number of Norwood procedures performed on randomized subjects per year (as a continuous
variable) and classified as #5, 5-10, 11-15, or .15 procedures/y
 Center volume as average number of Norwood procedures performed on randomized subjects per year (as continuous variable) and
classified as #10, 11-25, 26-40, or .40 procedures/y

Surgery for Congenital Heart Disease

surgical techniques and perioperative care that could occur
over a longer time.
To maximize enrollment, the number of secondary outcome measures is intentionally limited to minimize the number of extra measurements and thus the burden on subjects
and families. For example, although 48-hour electroencephalographic monitoring or head magnetic resonance imaging
might provide mechanistic data to explain abnormalities in
neurodevelopment, these studies are not included. In addition, the trial may be underpowered for some of the secondary end point analyses.

CHD

Importance of Knowledge to Be Gained
Techniques for management of congenital heart lesions
have been adopted solely on the basis of expert consensus
and retrospective analysis, rather than on data from prospective, randomized clinical trials. The primary goal of
the PHN is to promote evidence-based clinical care for children and adults with congenital heart disease. This trial offers a unique opportunity for systematic comparison of two
surgical procedures for which equipoise exists among surgeons and for determination of the time course of risk
and benefit for each procedure. Not only will the main results provide an unbiased estimate of relative efficacies of
the two shunts, but standardized information characterizing
the clinical course in a large unselected cohort of infants
with HLHS will be obtained for the first time. The results
of this study will make an important contribution to the
management of the highest-risk group of patients with congenital heart disease. Another important contribution of this
trial will be establishment of the basis for long-term followup of a well-characterized cohort of patients with little systematic information currently available. Finally, this trial
provides a feasible model of collaborative research for the
evaluation of other operative interventions in patients with
congenital cardiovascular malformations.
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